<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00198471</url>
  </required_header>
  <id_info>
    <org_study_id>ISTA-VIT-CS07</org_study_id>
    <nct_id>NCT00198471</nct_id>
  </id_info>
  <brief_title>Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment</brief_title>
  <official_title>An Open-label Assessment of Intravitreous Injections of Vitrase (Hyaluronidase for Injection) for Inducing Posterior Vitreous Detachment in Subjects With Moderate to Severe Non-proliferative Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of intravitreous injections of Vitrase to
      induce posterior vitreous detachment(PVD) in subjects with moderate to severe
      non-proliferative diabetic retinopathy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vitreous detachment</measure>
    <time_frame>Day 28</time_frame>
    <description>The proportion of subjects achieving a complete posterior vitreous detachment by Study Day 28</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment>10</enrollment>
  <condition>Vitreous Detachment</condition>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Vitrase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single intravitreous injection of Vitrase 93 USP Units (75 IU) on Study Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitrase</intervention_name>
    <arm_group_label>Vitrase</arm_group_label>
    <other_name>ovine hyaluronidase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderately severe to severe non-proliferative diabetic retinopathy

          -  Best Corrected Visual Acuity (BCVA) in Early Treatment Diabetic Retinopathy Study
             (ETDRS) with pinhole of 20/320 or better in study eye &amp; 20/50 or better in non-study
             eye.

        Exclusion Criteria:

          -  Contraindications or hypersensitivities to Vitrase or anesthesia

          -  Any significant illness that could be expected to interfere with trial

          -  Prior Vitrase therapy

          -  Either a past diagnosis of clinically significant macular edema (CME) in study eye
             that required treatment or current CME that may require focal laser treatment within
             the next 30 days

          -  For either eye: ongoing ocular infection, inflammation or history of herpetic corneal
             lesion; an intravitreous injection within 30 days; glaucoma; intraocular pressure
             (IOP) of less than 5mmHg; retinal detachment or ocular tumors

          -  For study eye: vascular occlusive disease of fundus; corneal, lenticular or ocular
             media abnormalities; a significant ocular trauma within 6 months; previous vitrectomy;
             any prior laser treatment, cryo-retinopexy or any intraocular surgery; either a
             partial or complete posterior vitreous detachment (PVD); myopia of 6 or more spherical
             diopters and/or axial length exceeding 26mm; significant retinal pathology
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon Williams, PhD</last_name>
    <role>Study Director</role>
    <affiliation>ISTA Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Edgar L. Thomas, MD</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ronni Lieberman, MD</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Retina Institute, PA</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Virginia Retina Center</name>
      <address>
        <city>Leesburg</city>
        <state>Virginia</state>
        <zip>20176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>March 13, 2013</last_update_submitted>
  <last_update_submitted_qc>March 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Dissociative Disorders</mesh_term>
    <mesh_term>Vitreous Detachment</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

